Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M A Bookman

Showing results (61-70 of 74) with videos related to

Pageof 8
Sort By:
Cancer Research|September 1, 1993
Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain FvG P Adams, J E McCartney, M S Tai, et al.
Protein Engineering|March 1, 1995
Engineering disulfide-linked single-chain Fv dimers [(sFv')2] with improved solution and targeting properties: anti-digoxin 26-10 (sFv')2 and anti-c-erbB-2 741F8 (sFv')2 made by protein folding and bonded through C-terminal cysteinyl peptidesJ E McCartney, M S Tai, R M Hudziak, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 1, 1995
Enhanced tumor specificity of 741F8-1 (sFv')2, an anti-c-erbB-2 single-chain Fv dimer, mediated by stable radioiodine conjugationG P Adams, J E McCartney, E J Wolf, et al.
Journal of the National Cancer Institute|April 19, 1989
Intraperitoneal lymphokine-activated killer cell/interleukin-2 therapy in patients with intra-abdominal cancer: immunologic considerationsW J Urba, J W Clark, R G Steis, et al.
Cancer Immunology, Immunotherapy : CII|May 1, 1995
Optimization of in vivo tumor targeting in SCID mice with divalent forms of 741F8 anti-c-erbB-2 single-chain Fv: effects of dose escalation and repeated i.v. administrationG P Adams, J E McCartney, E J Wolf, et al.
Gynecologic Oncology|October 31, 2006
Proceedings of a GOG workshop on intraperitoneal therapy for ovarian cancerD S Alberts, M Markman, F Muggia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1990
Intraperitoneal lymphokine-activated killer-cell and interleukin-2 therapy for malignancies limited to the peritoneal cavityR G Steis, W J Urba, L A VanderMolen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 13, 2017
Harmonising clinical trials within the Gynecologic Cancer InterGroup: consensus and unmet needs from the Fifth Ovarian Cancer Consensus ConferenceM A Bookman, A Okamoto, G Stuart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1996
Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancerP J O'Dwyer, T C Hamilton, F P LaCreta, et al.
Gynecologic Oncology|August 15, 2019
Measurements of adiposity as prognostic biomarkers for survival with anti-angiogenic treatment in epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group ancillary data analysis of GOG 218K N Slaughter Wade, M F Brady, T Thai, et al.
Pageof 8

Showing results (61-70 of 74) with videos related to

Sort By:
Pageof 8
Cancer Research|September 1, 1993
Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain FvG P Adams, J E McCartney, M S Tai, et al.
Protein Engineering|March 1, 1995
Engineering disulfide-linked single-chain Fv dimers [(sFv')2] with improved solution and targeting properties: anti-digoxin 26-10 (sFv')2 and anti-c-erbB-2 741F8 (sFv')2 made by protein folding and bonded through C-terminal cysteinyl peptidesJ E McCartney, M S Tai, R M Hudziak, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 1, 1995
Enhanced tumor specificity of 741F8-1 (sFv')2, an anti-c-erbB-2 single-chain Fv dimer, mediated by stable radioiodine conjugationG P Adams, J E McCartney, E J Wolf, et al.
Journal of the National Cancer Institute|April 19, 1989
Intraperitoneal lymphokine-activated killer cell/interleukin-2 therapy in patients with intra-abdominal cancer: immunologic considerationsW J Urba, J W Clark, R G Steis, et al.
Cancer Immunology, Immunotherapy : CII|May 1, 1995
Optimization of in vivo tumor targeting in SCID mice with divalent forms of 741F8 anti-c-erbB-2 single-chain Fv: effects of dose escalation and repeated i.v. administrationG P Adams, J E McCartney, E J Wolf, et al.
Gynecologic Oncology|October 31, 2006
Proceedings of a GOG workshop on intraperitoneal therapy for ovarian cancerD S Alberts, M Markman, F Muggia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1990
Intraperitoneal lymphokine-activated killer-cell and interleukin-2 therapy for malignancies limited to the peritoneal cavityR G Steis, W J Urba, L A VanderMolen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 13, 2017
Harmonising clinical trials within the Gynecologic Cancer InterGroup: consensus and unmet needs from the Fifth Ovarian Cancer Consensus ConferenceM A Bookman, A Okamoto, G Stuart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1996
Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancerP J O'Dwyer, T C Hamilton, F P LaCreta, et al.
Gynecologic Oncology|August 15, 2019
Measurements of adiposity as prognostic biomarkers for survival with anti-angiogenic treatment in epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group ancillary data analysis of GOG 218K N Slaughter Wade, M F Brady, T Thai, et al.
Pageof 8